Prenetics CEO Discusses New Joint Venture

Prenetics, initially a genetic testing company, pivoted during COVID-19 to address pandemic needs. Now, they are focusing on a $200 million joint venture with Professor Dennis Lowe to develop FRAGMA, an epigenetics-based early cancer detection technology. This innovation aims to make cancer screening affordable and accessible, with a target cost of $200 per test. Initial trials will focus on lung and liver cancer in China, with plans to expand globally. Prenetics anticipates significant revenue by 2025 and aims to launch a test detecting multiple cancers by 2027. They are also exploring partnerships with governments and institutions to revolutionize healthcare.

What is the significance of early cancer detection according to the text?

What is the projected annual number of tests Prenetics expects by 2030?

How does Prenetics plan to collaborate with governments and institutions?